Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PDF-1-derived peptide is a synthetic 37-amino acid peptide derived from the *C. elegans* pigment dispersing factor-1 (PDF-1) protein. Research indicates that PDF-1 and its receptor (PDF1R) share structural homology with the mammalian incretin family, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). In preclinical models of diet-induced obesity, the peptide has demonstrated the ability to suppress body weight gain, reduce food intake, and significantly improve insulin sensitivity. Its metabolic effects are associated with the up-regulation of brown fat activity markers such as Ucp1 and Cidea, as well as increased glucose uptake in muscle cells. It is being investigated as a potential novel backbone for the treatment of obesity and type 2 diabetes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PDF-1-derived peptide.